Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avacta Group plc ( (GB:AVCT) ) just unveiled an announcement.
Avacta Therapeutics, a clinical-stage biopharmaceutical arm of Avacta Group plc, is developing its proprietary pre|CISION tumor-activated delivery platform to improve the safety and efficacy of highly potent cancer therapies. Its pipeline is led by faridoxorubicin (AVA6000), a FAP-enabled version of doxorubicin, and AVA6103, a second clinical candidate designed for sustained intratumoral payload release while minimizing systemic toxicity.
Avacta announced it will publish unaudited preliminary results for the year ended December 31, 2025 on May 19, 2026, and senior management will host an online investor presentation that day via the Investor Meet Company platform. The event, open to existing and potential shareholders, underscores the company’s engagement with investors and will provide an update on financial performance and strategic progress, with materials also to be made available on its website.
Spark’s Take on AVCT Stock
According to Spark, TipRanks’ AI Analyst, AVCT is a Neutral.
Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on AVCT stock, click here.
More about Avacta Group plc
Avacta Therapeutics, part of Avacta Group plc, is a clinical-stage biopharmaceutical and life sciences company focused on oncology. It is developing its proprietary pre|CISION platform, a tumor-activated delivery system designed to concentrate potent cancer drug payloads in the tumor microenvironment while limiting exposure in healthy tissue. The company’s lead program is faridoxorubicin (AVA6000), a FAP-enabled version of doxorubicin, which has shown preliminary activity in cancers such as salivary gland cancer and soft tissue sarcoma, and it is also advancing AVA6103, a second FAP-based candidate in a Phase 1 trial for cancers with unmet needs.
Average Trading Volume: 2,171,986
Technical Sentiment Signal: Buy
Current Market Cap: £360.9M
For an in-depth examination of AVCT stock, go to TipRanks’ Overview page.